You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: 102

    Cost-effective and minimally invasive monitoring of metastatic breast cancer (MBC) patients for disease progression or response to therapy is an unmet need in the clinical management of the disease. Imaging technologies are currently the gold standard of such monitoring. However, there is controversy regarding the type and frequency of imaging required. Imaging is expensive, time consuming, slow t ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2

    SBC: ENCODIA INC            Topic: 100

    ABSTRACT The goal of this proposal is to repurpose technology developed for Next-Gen Proteomics to develop a highly-scalable digital serotyping technology for infectious disease analysis, with particular application to influenza and Covid-19. The approach is broadly applicable and should greatly improve upon cost, sensitivity, usability, and throughput of population-level serotyping and greatly im ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: 102

    Innew cases of breast cancerBCandrelated deaths are expected in the USof these are patients with aggressive triple negative BCTNBCor anti estrogen aromatase inhibitor resistantAE AIBC that do not have targeted therapy and rely on radiotherapy and aggressive chemotherapyA new approach that benefits these patients and provides increased life expectancy needs to be developedWe have identified GPa gly ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. TB Diagnostics at the Point of Care

    SBC: AKONNI BIOSYSTEMS INC            Topic: NIAID

    ABSTRACT Tuberculosis ranks in the top ten worldwide cause of death and now ranks ahead of HIV, making it the number one infectious disease killer. Perhaps, most alarming is the global prevalence of multidrug-resistant TB (MDR- TB) and extensively drug-resistant TB (XDR-TB): more than 5% of new TB cases are MDR-TB and 10% of these have XDR-TB. And, the number of enrolled XDR-TB cases has grown fro ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization of an Ultrasound-guided Vascular Access Device

    SBC: PERCEPTIVE NAVIGATION LLC            Topic: NHLBI

    PROJECT SUMMARY Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular and cardiothoracic diseases. An interventional catheter with forward-viewing ultrasound imaging capability will be developed to enable image-guided access to blood vessels and internal organs. Phase 1 and 2 experiments demonstrate feasibility of building a high res ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Data Intelligence & Advanced Analytics to Reduce Drug Diversion across the Care Delivery Cycle and Drug Supply Chain in Health Systems

    SBC: Invistics Corporation            Topic: NIDA

    This SBIR project will research mechanisms to detect when Health Care WorkersHCWsin hospitals steal ordivertlegal drugs either to abuse themselves or to illegally sell to othersWe focus on HCWs in hospitals because of the alarming rates of substance abuse and diversion in hospitalswith multiple studies finding roughlyof our nation s nursesanesthesiologistsand pharmacists are currently diverting dr ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Interactive Training in Emergency Operations for the Response Community

    SBC: GRYPHON SCIENTIFIC, LLC            Topic: NIEHS

    In this competitive revision Phase II SBIR, Gryphon Scientific proposes to expand the scope of the ongoing project to support the urgent need to develop and deploy training for two populations of citizen responders at risk of coronavirus exposure. The ongoing Phase II SBIR project focuses on training responders, including Community Emergency Response Teams (CERT) and the Medical Reserve Corps (MRC ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting

    SBC: AMELIA TECHNOLOGIES LLC            Topic: NIEHS

    Regulatory agencies including EPAFDAECHAand EMA require thorough assessment of the health effects of chemicals present in the environment and marketplaceInterpretation of positive genotoxicity findings using the current standard in vitro testing battery is a major challenge to both industry and regulatory agenciesThese tests have high sensitivitybut suffer from low specificityleading to high rates ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of NanoShield for Ambient handling of labile Bio-products

    SBC: Topogen, Inc            Topic: 300

    Project Summary TopoGENin a strategic partnership with Nanoly Bioscienceproposes to develop ambient condition stable Research Use OnlyRUOproductse genzymesantibodiesand Kitsthrough the use of a syntheticsafeand biocompatible polymer encapsulation technologyNanoShieldNanoShield uses a patent protected photodegradable polyethylene glycolPEGhydrogel network to encapsulate and shield sensitive biomole ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government